source
- Beam Therapeutics reports successful pivotal trial of base editing sickle cell therapyBeam Therapeutics announced that its base editing treatment, ristoglogene autogetemcel (risto‑cel), met its primary goal in a pivotal trial for sickle cell disease. The trial showed the therapy cou…
- AstraZeneca acquires Omniose to boost bacterial vaccine capabilitiesAstraZeneca has completed the purchase of Omniose, a specialist in vaccine bioconjugation, making the company a wholly owned subsidiary of its infectious disease division. The two firms began coll…